ABBV-932 / AbbVie, Gedeon Richter - LARVOL DELTA

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: AbbVie | Trial completion date: Nov 2025 ➔ Feb 2027 | Trial primary completion date: Nov 2025 ➔ Feb 2027

Adverse events • Trial completion date • Trial primary completion date • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

M24-991: Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers (clinicaltrialsregister.eu) - P1 | N=8 | Active, not recruiting | Sponsor: AbbVie Deutschland GmbH & Co. KG | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2026 ➔ Sep 2026 | Trial primary completion date: Feb 2026 ➔ Sep 2026

Enrollment open • Trial completion date • Trial primary completion date

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | N=42 ➔ 9

Enrollment change • Enrollment closed

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: AbbVie | N=28 ➔ 42

Enrollment change

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (clinicaltrials.gov) - P2 | N=161 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Adverse events • Trial completion • Bipolar Disorder • CNS Disorders • Depression • Psychiatry

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: AbbVie | Recruiting ➔ Completed | N=30 ➔ 20

Adverse events • Enrollment change • Trial completion

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Bipolar Disorder • CNS Disorders • Depression • Psychiatry

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: AbbVie | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Nov 2025 ➔ Mar 2026

Enrollment open • Trial completion date • Trial primary completion date

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • Bipolar Disorder • CNS Disorders • Depression

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: AbbVie | Trial completion date: Sep 2025 ➔ Feb 2026 | Initiation date: May 2025 ➔ Oct 2025 | Trial primary completion date: Sep 2025 ➔ Feb 2026

Trial completion date • Trial initiation date • Trial primary completion date

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P1 trial

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder (clinicaltrials.gov) - P2 | N=315 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: AbbVie

New P1 trial